Federated Hermes’s Elicio Therapeutics ELTX Stock Holding History

Federated Hermes’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35	Closed	-$1K	–	2190
2022 Q1	$1K	Buy	+35	New	+$790	﹤0.01%	2088

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Federated Hermes's ELTX Position: Q2 2022 in Review

Federated Hermes sold out of Elicio Therapeutics (ELTX) in Q2 2022, closing a stake of 35 shares — an estimated $1K sold.

Federated Hermes first reported a position in ELTX in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 43 funds tracked by Wall St. Rank hold ELTX as of Q2 2022.

Federated Hermes reported no remaining Elicio Therapeutics position as of Q2 2022 after selling out during the quarter.
Federated Hermes sold 35 Elicio Therapeutics shares in Q2 2022, an estimated $1K.
Federated Hermes first reported a position in Elicio Therapeutics in Q1 2022 and held it in 1 quarter.
Federated Hermes's Elicio Therapeutics position peaked at $1K in Q1 2022.
43 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.